Correlogic Systems' OvaCheck, the blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test.
OvaCheck is a multivariate index assay that measures the relative ratios of eight proteins. It employs a bead-based multiplexed immunoassay platform and Correlogic’s proprietary software system to return a result.
The simple blood test will help physicians more accurately determine whether a pelvic mass is ovarian cancer leading to earlier, appropriate treatment and fewer unnecessary surgeries.
Correlogic is currently in discussions with potential partners for distribution of OvaCheck in Europe.
Peter Levine, CEO of Correlogic, said: “Accurate detection of ovarian cancer has been elusive, but it is essential to saving lives. OvaCheck can be a powerful tool for earlier, more accurate detection of ovarian cancer without an invasive procedure a real advancement in confronting this disease.”
Correlogic Systems uses pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests.